Granules India Promoter sells 3.09 pecent stake for Rs 304 crore
Hyderabad: Krishna Prasad Chigurupati, a promoter of Granules India, has sold a 3.09 percent stake in the company for Rs 304 crore through an open market transaction. According to data from the NSE's block deal, Chigurupati sold 75 lakh shares of Granules India.
Dr. Krishna Prasad Chigurupati’s holding as a Promoter of the Company has changed from 34.78 % to 31.69 % of the Paid-up equity share capital of the Company.
According to PTI, Axis Mutual Fund, Dendana Investments (Mauritius), Fidelity Funds India Focus Fund, Fidelity India Fund, Fidelity Korea - India Equity Investment Trust-Mother and Long Term Equity Fund were among the buyers of shares of Granules India.
Read also: Granules India arm gets USFDA nod for Gout flares drug Colchicine
Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered in Hyderabad. The Company is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Its products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, U.S. and U.K. The Company has 7 manufacturing facilities out of which 6 are located in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.
Read also: Granules India bags USFDA nod for Pantoprazole Sodium Delayed Release Tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.